GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » Pretax Margin %

ITeos Therapeutics (ITeos Therapeutics) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is ITeos Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. ITeos Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-36.00 Mil. ITeos Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, ITeos Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for ITeos Therapeutics's Pretax Margin % or its related term are showing as below:


ITOS's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.03
* Ranked among companies with meaningful Pretax Margin % only.

ITeos Therapeutics Pretax Margin % Historical Data

The historical data trend for ITeos Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Pretax Margin % Chart

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial - - 74.39 55.58 -865.66

ITeos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -113.95 - - - -

Competitive Comparison of ITeos Therapeutics's Pretax Margin %

For the Biotechnology subindustry, ITeos Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ITeos Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's Pretax Margin % falls into.



ITeos Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

ITeos Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-109.03/12.595
=-865.66 %

ITeos Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-36.002/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ITeos Therapeutics  (NAS:ITOS) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


ITeos Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics (ITeos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
321 Arsenal Street, Watertown, MA, USA, 02472
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Matthew Gall officer: Chief Financial Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Michel Detheux director, officer: Chief Executive Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Yvonne Mcgrath officer: VP, Research and Development C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Joanne Jenkins Lager officer: Chief Medical Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Detlev Biniszkiewicz director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Tony W Ho director CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Robert Iannone director 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950

ITeos Therapeutics (ITeos Therapeutics) Headlines

From GuruFocus

iTeos to Present at the Cowen 42nd Annual Health Care Conference

By GuruFocusNews GuruFocusNews 03-01-2022

NCR Atleos Set to Join S&P SmallCap 600

By PRNewswire 10-11-2023

Insider Alert: An Insider Just Sold ITeos Therapeutics Inc Shares

By GuruFocus Research GuruFocus Editor 03-23-2022

iTeos to Present at SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-07-2023